医药商业贿赂处罚新政已逐步落地

2018-01-18 医药史立臣 MedSci原创

2018年1月1日起,历经24年首次修订的新版《反不正当竞争法》实施,重新定义商业贿赂:买卖双方主体之外的第三方,帮助买方购买或者帮助卖方销售,从而获取一定利益的行为。

      2018年1月1日起,历经24年首次修订的新版《反不正当竞争法》实施,重新定义商业贿赂:买卖双方主体之外的第三方,帮助买方购买或者帮助卖方销售,从而获取一定利益的行为。       著名经济学家宋清辉认为,医药行业公司的市场及学术推广费一直都是商业贿赂的高发区,以步长制药为例,公司2013-2015年市场及学术推广费用分别约为44.66亿元、51.83亿元以及58.41亿元,占同期销售费用总额的比例高达89.69%、86.79%、88.87%,同时销售费用占营收为57.96%、57.79%、56.39%,大幅高于同行业水平。而在上市后,步长制药2016年的市场及学术推广费达到新高60.13亿,占同期销售费用的87.78%,同时销售费用占营收比高达55.6%。其居高不下的市场及学术推广费用也会存在侵蚀公司业绩的风险。  诸多政策开始实施落地       值得注意的是,2017年11月,新版《反不正当竞争法》通过全国人大审议后,上海工商局在年末集中公

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771772, encodeId=264f1e7177215, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Nov 10 11:08:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006623, encodeId=1921200662374, content=<a href='/topic/show?id=ff804006995' target=_blank style='color:#2F92EE;'>#商业贿赂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40069, encryptionId=ff804006995, topicName=商业贿赂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Sep 05 16:08:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409292, encodeId=146914092924e, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 20 08:08:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535059, encodeId=60d8153505952, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Jan 20 08:08:00 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1771772, encodeId=264f1e7177215, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Nov 10 11:08:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006623, encodeId=1921200662374, content=<a href='/topic/show?id=ff804006995' target=_blank style='color:#2F92EE;'>#商业贿赂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40069, encryptionId=ff804006995, topicName=商业贿赂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Sep 05 16:08:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409292, encodeId=146914092924e, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 20 08:08:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535059, encodeId=60d8153505952, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Jan 20 08:08:00 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1771772, encodeId=264f1e7177215, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Nov 10 11:08:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006623, encodeId=1921200662374, content=<a href='/topic/show?id=ff804006995' target=_blank style='color:#2F92EE;'>#商业贿赂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40069, encryptionId=ff804006995, topicName=商业贿赂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Sep 05 16:08:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409292, encodeId=146914092924e, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 20 08:08:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535059, encodeId=60d8153505952, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Jan 20 08:08:00 CST 2018, time=2018-01-20, status=1, ipAttribution=)]
    2018-01-20 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1771772, encodeId=264f1e7177215, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Sat Nov 10 11:08:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006623, encodeId=1921200662374, content=<a href='/topic/show?id=ff804006995' target=_blank style='color:#2F92EE;'>#商业贿赂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40069, encryptionId=ff804006995, topicName=商业贿赂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Wed Sep 05 16:08:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409292, encodeId=146914092924e, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Jan 20 08:08:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535059, encodeId=60d8153505952, content=<a href='/topic/show?id=3df58e521e9' target=_blank style='color:#2F92EE;'>#药商#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87521, encryptionId=3df58e521e9, topicName=药商)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c72d12584423, createdName=soongzhihua, createdTime=Sat Jan 20 08:08:00 CST 2018, time=2018-01-20, status=1, ipAttribution=)]

相关资讯

空有虚名!盘点广东18家持C证却并未开通网上药店的企业

今起,笔者独家推出《盘点那些获得C证却未开通网上药店的企业》系列文章,找寻那些取消审批背后的又一诱因,预测医药电商的春冬……

麦斯康莱:中医诊所备案制完善 市场规模或大幅扩张

近日,国家卫计委发布《中医诊所备案管理暂行办法》(下称《暂行办法》):今后举办中医诊所,报所在地县级中医药主管部门备案后,即可开展执业活动,即由审批制改为备案制。《暂行办法》将于12月1日正式实施。

很多药企已经开始在转型路上

真正想要说的是,一些药企真的开始了积极转型之路,而且,业绩喜人,哪些还在观望等待的药企,实在应该好好规划一下未来的路怎么走了。

中医诊所开办门槛将降低 中医药或迎春天

自今年7月《中医药法》落地后,备受业界关注的“中医诊所备案制”也即将落地。日前,国家卫计委发布《中医诊所备案管理暂行办法》,指出符合资格的个人办中医诊所,只需向当地中医药主管部门备案后即可开展执业活动。《暂行办法》将在12月1日正式实施。